Ackman Uses Interesting Strategy, Including 'Superman' In Zoetis BidMark Melin
In setting up his next target, Zoetis Inc (NYSE:ZTS), activist hedge fund manager Bill Ackman has utilized an interesting combination of derivatives and may be employing a new tactic with a potential partner in a takeover bid, namely with the rumored involvement of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX).
Several weeks ago, as Pershing Square Capital was in court with Allergan, Inc. (NYSE:AGN), Ackman’s hedge fund acquired roughly 41.8 million . . .
This content is exclusively for paying members. Sign up here
If you are subscribed and having an account error please clear cache and cookies if that does not work email email@example.com or click chat